This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Meropol NJ , Somer RA , Gutheil J , Pelley RJ , Modiano MR , Rowinsky EK , Rothenberg ML , Redding SW , Serdar CM , Yao B , Heard R , Rosen LS
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: Potential role as mucosal protectant
Journal of Clinical Oncology. 2003 Apr 15;21(8) :1452-1458
AbstractPurpose: To evaluate the safety of recombinant human keratinocyte growth factor (KGF) when administered with fluorouracil (FU) in patients with metastatic colorectal cancer.Patients and Methods: Patients (N = 81) received KGF by intravenous (IV) bolus on days 1 to 3, followed by FU 425 mg/m(2)/d IV bolus plus leucovorin 20 mg/m(2)/d IV on days 4 to 8. KGF dose levels were 1, 10, 20, 40, 60, and 80 mug/kg/d. A randomized, placebo-controlled design was employed (2:1 randomization of KGF to placebo). Oral mucositis was assessed by examination on days 1, 4, 8, 15, and 28. In addition, patients provided daily assessments of oral symptoms using a self-administered questionnaire.Results: Skin and oral events occurred in 13 of 18 patients (eight patients, grade 1; four patients, grade 2; and one patient, grade 3) treated with 60 and 80 mug/kg of KGF and three of 1 1 patients treated with 40 mug/kg (grade 1). These symptoms were dose limiting in three cases (ie, in two of 10 patients treated with 80 mug/kg and in one of eight patients treated with 60 mug/kg). The frequency of grade 2 to 4 mucositis was 43% in patients treated with KGF, compared with 67% in patients treated with placebo (P = .06). Patient self-assessments of oral pain and clinical assessments of mucositis showed good correlation (Kendall's tau = 0.75).Conclusion: KGF is generally well tolerated when administered IV at doses up to 40 wg/kg/d for 3 days before a 5-day course of FU plus leucovorin. A clinically meaningful biologic effect was also suggested in that patients treated with the epithelial growth factor KGF had a lower rate of grade 2 to 4 mucositis than did patients treated with placebo. (C) 2003 by American Society of Clinical Oncology.
NotesMeropol, NJ,Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA Article English